Cellectis (CLLS) Net Cash Flow Growth (1y) (2016 - 2026)
Cellectis (CLLS) Net Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 53.46% |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - | -55.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.49% |
| Dec 31, 2025 | 157.69% |
| Sep 30, 2025 | -175.47% |
| Jun 30, 2025 | -377.39% |
| Mar 31, 2025 | -26.41% |
| Dec 31, 2024 | -121.54% |
| Sep 30, 2024 | 178.22% |
| Jun 30, 2024 | 4,143.50% |
| Mar 31, 2024 | -93.98% |
| Dec 31, 2023 | 1,088.71% |
| Sep 30, 2023 | 39.44% |
| Jun 30, 2023 | 96.37% |
| Mar 31, 2023 | 79.20% |
| Dec 31, 2022 | 114.96% |
| Sep 30, 2022 | 29.07% |
| Jun 30, 2022 | -140.96% |
| Mar 31, 2022 | -8.26% |
| Dec 31, 2021 | -312.02% |
| Sep 30, 2021 | -438.77% |
| Jun 30, 2021 | 246.44% |